Featured Research

from universities, journals, and other organizations

Positive results for unprotected left main coronary artery PCI with drug-eluting stents

Date:
June 22, 2011
Source:
Wiley-Blackwell
Summary:
Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research, according to results of a multicenter, retrospective study.

Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).

Related Articles


For patients with ULMCA disease, coronary artery bypass grafting (CABG), known commonly as heart bypass surgery, is the standard of care based on medical evidence that shows a survival advantage with this intervention. Current guidelines for PCI state that ULMCA stenting may be an option for patients who are at high risk for adverse surgical outcomes, but have a low risk for procedural complications. In patients with severe aortic calcification, cerebrovascular disease, or limited life expectancy angioplasty may be elected over heart bypass surgery.

The present study, led by Michael Lee, MD, FSCAI, from the University of California, Los Angeles (UCLA) Medical Center evaluated the safety and efficacy of ULMCA PCI with DES in patients with normal left ventricular function. Researchers used data from a multicenter international registry, identifying 221 patients who underwent elective PCI for ULMCA disease between 2002 and 2009. Patients in the study had a mean age of 68 years and 75% were male; 25% had diabetes, 39% had a history of heart attack, and 40% had a prior PCI.

"Our analysis confirms that elective PCI with DES in patients with normal left ventricular function is a safe and effective treatment for ULMCA disease," said Dr. Lee. In the first 30 days following angioplasty no cardiac death, target lesion revascularization (TLR), stent thrombosis, or stroke were reported. While no cases of Q-wave myocardial infarction occurred, seven patients had periprocedural myocardial infarction.

The authors found that event-free survival estimates for cardiac death and TLR at five years was 96% and 89%, respectively. Further analysis established that patient age of 75 years or older and a history of myocardial infarction were independent predictors of cardiac death. "Research comparing the safety and efficacy of ULMCA PCI with DES versus CABG are needed and results from a large multicenter trial are forthcoming." Dr Lee concluded, "ULMCA PCI may be a viable option for low-risk patients with normal left ventricular function."


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Michael S. Lee, Tae Yang, Giuseppe Biondi-Zoccai, Dario Sillano, Enrico Cerrato, Giuseppe Tarantini, Jola Xhaxho, Joseph Aragon, Imad Sheiban. Long-term outcomes of elective drug-eluting stenting of the unprotected left main coronary artery in patients with normal left ventricular function. Catheterization and Cardiovascular Interventions, 2011; 77 (7): 945 DOI: 10.1002/ccd.22777

Cite This Page:

Wiley-Blackwell. "Positive results for unprotected left main coronary artery PCI with drug-eluting stents." ScienceDaily. ScienceDaily, 22 June 2011. <www.sciencedaily.com/releases/2011/06/110622115427.htm>.
Wiley-Blackwell. (2011, June 22). Positive results for unprotected left main coronary artery PCI with drug-eluting stents. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2011/06/110622115427.htm
Wiley-Blackwell. "Positive results for unprotected left main coronary artery PCI with drug-eluting stents." ScienceDaily. www.sciencedaily.com/releases/2011/06/110622115427.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins